Fractyl Health, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
Fractyl Health, Inc. (GUTS) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 5.50% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2026-03-24
- Fractyl Health, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2024 was 5.50%, a 103.70% increase from fiscal 2023.
- Fractyl Health, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2023 was 2.70%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2024-12-31 | 5.50% 10-K · filed 2026-03-24 |
| 2023-12-31 | 2.70% 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RenovoRx, Inc. (RNXT) | United States | $0.076B | -3.62 |
| Pulmonx Corp (LUNG) | United States | $0.082B | -1.16 |
| CVRx, Inc. (CVRX) | United States | $0.067B | -2.62 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 | |
| SkinHealth Systems Inc. (SKIN) | United States | $0.086B | -3.17 |
| LENSAR, Inc. (LNSR) | United States | $0.087B | 2.02 |
| Microbot Medical Inc. (MBOT) | $0.089B | -7.97 | |
| TELA Bio, Inc. (TELA) | United States | $0.057B | -0.82 |
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B | |
| Spectral AI, Inc. (MDAI) | United States | $0.052B |